Petrie, J.R. (2009) Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 360(4), pp. 416-417.
Full text not currently available from Enlighten.
Publisher's URL: http://www.nejm.org/doi/full/10.1056/NEJMc082275
Abstract
In the original UKPDS trial, when metformin was prescribed for patients who were already receiving a sulfonylurea, there was a significant increase in the risk of diabetes-related death and death from any cause. These results were attributed to a small number of end points, and they were in contrast to the positive results associated with metformin monotherapy, which have, of course, been highly influential in shaping modern clinical practice. The new data in the 10-year post-randomization follow-up show positive results associated with metformin in general, but no separate information has so far been provided regarding the subgroup of patients receiving combination therapy. Given the additional accumulation of end points, can the authors provide reassurance regarding this clinically important issue?
Item Type: | Articles (Letter) |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Petrie, Professor John |
Authors: | Petrie, J.R. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health College of Medical Veterinary and Life Sciences |
Journal Name: | New England Journal of Medicine |
Publisher: | Massachusetts Medical Society |
ISSN: | 0028-4793 |
ISSN (Online): | 1533-4406 |
Published Online: | 01 January 2009 |
University Staff: Request a correction | Enlighten Editors: Update this record